Scientists investigate why immunotherapy attacks the nervous system

NCT ID NCT07456358

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study looks at why some cancer patients develop neurological problems after receiving immunotherapy drugs called checkpoint inhibitors. Researchers will analyze spinal fluid and blood from 160 participants to find immune cells that may mistakenly attack the nervous system. The goal is to better understand the causes of these side effects, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors predict or prevent nerve-related side effects in cancer patients receiving immunotherapy.
What could go wrong: This is an observational study, not a treatment trial. It is still in early stages and may not lead to direct clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (aged ≥ 18 years) * Affiliated with a social security scheme * Express consent to participate in the study * Indication for lumbar puncture And * Patients with cancer, undergoing treatment with ICIs, presenting neurological symptoms after starting treatment with ICIs. These symptoms must have appeared no more than 3 months after the last administration of ICIs. Or * Patients with an autoimmune disease of the central nervous system (diagnosis made by teams 1, 2 and 3) according to internationally recognised criteria, with no history of active cancer in the last 3 years and no other autoimmune disease Or * Patients with normal pressure hydrocephalus (NPH) or idiopathic intracranial hypertension (diagnosed based on imaging (brain MRI) and clinical findings), with no history of active cancer in the last 3 years and no active autoimmune disease Exclusion Criteria: * Contraindication or refusal to perform a lumbar puncture * Sample not suitable for research (volume of CSF collected for treatment \>5 mL) * Corticosteroid therapy or other immunomodulatory treatment in progress (discontinued less than 15 days prior to inclusion) * Pregnant or breastfeeding women * Not affiliated with the social security system, patients under French State Medical Aid for undocumented migrants * Patients under guardianship or curatorship, under judicial protection measures, or deprived of their liberty by judicial or administrative decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Auto immune disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease autoimmune disorder of central nervous system nervous system disorder normal pressure hydrocephalus pseudotumor cerebri

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Auto immune disease Neurological diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

4 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Scientists investigate why immunotherapy attacks the nervous system

What the study statuses mean